Janux Therapeutics Inc
NASDAQ:JANX
Janux Therapeutics Inc
NASDAQ:JANX
Price:
47.51 USD
0.06%
Updated:
May 17, 2024
EV/S
Enterprise Value to Sales
Enterprise Value to Sales
248.3
Current
35.8
Median
7.5
Industry
Higher
than median
Higher
than industry value
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
EV/S
=248.3
Enterprise Value
/
1.8B
Revenue
7.3m
All Countries
| Market Cap | EV/S | ||||
|---|---|---|---|---|---|
| US |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
2.5B USD | 248.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.2B USD | 6.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.8B USD | 7.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 10.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.7B USD | 7.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 7.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 2.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.8B USD | 8.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.2 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.5B USD | 4 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.4T KRW | 18.6 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/S
896.2
2-Years Forward
EV/S
1 381.5
3-Years Forward
EV/S
129.1
You don't have any saved screeners yet
